Maiwald
Lawyers at Maiwald and Sterne Kessler analyse how patents with claims directed to medical treatments are handled in the US and in Europe
Sponsored
Sponsored
-
Sponsored by Maiwald Intellectual PropertySenior Maiwald lawyers outline the strategy behind the firm’s recognition as EPO Proceedings Firm of the Year at the Managing IP EMEA Awards 2025 and discuss key developments in the European intellectual property space -
Sponsored by Maiwald Intellectual PropertyAnnelie Wünsche of Maiwald Intellectual Property summarises the EU’s proposed update to the supplementary protection certificate system for medicinal products, highlighting key procedural shifts, the role of the EUIPO, and ongoing debate over the most suitable examining authority
-
Sponsored by Maiwald Intellectual PropertyWilhelm Eger of Maiwald Intellectual Property examines how the Pemetrexed case has influenced European approaches to patent infringement under the doctrine of equivalency and how numbers and measurements are addressed
-
Sponsored by Maiwald Intellectual PropertyGerman courts are now permitting the service of claims on Chinese respondents by publication to ensure effective legal protection. Marco Stief of Maiwald contrasts this approach with the Unified Patent Court’s stricter stance
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer and Gisela Grabow of Maiwald explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster competition and enhance patient access
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer and Gisela Grabow of Maiwald consider proposals under the European Commission’s Action Plan for Intellectual Property that aim to simplify extended protection for medicinal products through a unitary supplementary protection certificate
